U.S. Appeals Court Says Eisai Patents Can Be Challenged By Teva
This article was originally published in PharmAsia News
Executive Summary
A U.S. appeals court ruled Eisai patents for its Aricept (donepezil) Alzheimer's drug are open to challenge by generics maker Teva Pharmaceutical Industries of Israel